Tralokinumab (Adbry, LEO Pharma) in AD: Reviewing New Data From the ECZTRA 3 and ECZTEND Trials With Dr. Andy Blauvelt September 24, 2025
From the Podium to Your Practice: Dr. Christopher Bunick Discusses New Real-world Safety Data on Upadacitinib (Rinvoq, AbbVie) in AD September 19, 2025
Breaking News: U.S. FDA Approves Ruxolitinib Cream 1.5% (Opzelura, Incyte) for Kids Age 2 and up With AD September 18, 2025
AD Pipeline Watch: Rezpegaldesleukin Hits Primary and Key Secondary Endpoints in REZOLVE-AD Phase 2b Study September 18, 2025